Maurice Stephan Michel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maurice Stephan Michel has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Peter Alken
Universitätsklinikum Mannheim
7 shared publications - Lutz Trojan
Department of Urology, University Hospital Mannheim, Mannheim, Germany
6 shared publications Christel Weiss
3 shared publications- Rainer Grobholz
Medical Faculty, University of Zurich, Zurich, Switzerland
3 shared publications Annette Steidler
2 shared publications- Christian Bolenz
Department of Urology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
2 shared publications
Latest Publications
- 6 July 2009
- Published by Spandidos Publications in Oncology Reports
- Vol. 22 (2) , 321-326
Paclitaxel encapsulated in cationic liposomes: A new option for neovascular targeting for the treatment of prostate cancer
Neovascular targeting is an established approach for the therapy of prostate cancer (PCa). Cationic liposomes have been shown to be absorbed by immature vascular endothelial cells due to negative electric charge of their outer cell membrane. We aimed to evaluate the antitumoural efficacy of paclitaxel encapsulated in cationic liposomes for the treatment of PCa. Tumours were generated by subcutaneous injection of 106 MatLu tumour cells into the right hind leg of 21 male Copenhagen rats. After tumour growth, the animals were treated by an i.v. infusion with either 5% glucose (Gl), paclitaxel (Pax), cationic liposomes (CL) or paclitaxel encapsulated in cationic liposomes (EndoTAG-1) on days 12, 14, 16 and 19. Treatment was initiated on day 12 after tumour inoculation at mean tumour volumes of 0.31±0.13 mm3. On the last day of treatment, animals treated with EndoTAG-1 had the significantly lowest tumour volumes with 2.49±0.84 cm3 vs. Pax (5.59±0.45 cm3) vs. CL (3.87±1.25 cm3) vs. GL (5.17±1.70 cm3). The quantification of MVD showed the lowest count for EndoTAG-1-treated tumours (11.78±2.68 vessels/mm2) followed by Gl (15.64±6.68 vessels/mm3), Pax (18.22±9.50 vessels/mm3) and CL (40.9±32.8 vessels/mm3). The data confirm that neovascular targeting with EndoTAG-1 is a promising new method for the treatment of PCa by reducing the primary tumour mass and demonstrating benefits in the suppression of angiogenesis in comparison with the conventional treatment.
- 6 July 2009
- Published by Spandidos Publications in Oncology Reports
- Vol. 22 (2) , 321-326
Paclitaxel encapsulated in cationic liposomes: A new option for neovascular targeting for the treatment of prostate cancer
Neovascular targeting is an established approach for the therapy of prostate cancer (PCa). Cationic liposomes have been shown to be absorbed by immature vascular endothelial cells due to negative electric charge of their outer cell membrane. We aimed to evaluate the antitumoural efficacy of paclitaxel encapsulated in cationic liposomes for the treatment of PCa. Tumours were generated by subcutaneous injection of 106 MatLu tumour cells into the right hind leg of 21 male Copenhagen rats. After tumour growth, the animals were treated by an i.v. infusion with either 5% glucose (Gl), paclitaxel (Pax), cationic liposomes (CL) or paclitaxel encapsulated in cationic liposomes (EndoTAG-1) on days 12, 14, 16 and 19. Treatment was initiated on day 12 after tumour inoculation at mean tumour volumes of 0.31±0.13 mm3. On the last day of treatment, animals treated with EndoTAG-1 had the significantly lowest tumour volumes with 2.49±0.84 cm3 vs. Pax (5.59±0.45 cm3) vs. CL (3.87±1.25 cm3) vs. GL (5.17±1.70 cm3). The quantification of MVD showed the lowest count for EndoTAG-1-treated tumours (11.78±2.68 vessels/mm2) followed by Gl (15.64±6.68 vessels/mm3), Pax (18.22±9.50 vessels/mm3) and CL (40.9±32.8 vessels/mm3). The data confirm that neovascular targeting with EndoTAG-1 is a promising new method for the treatment of PCa by reducing the primary tumour mass and demonstrating benefits in the suppression of angiogenesis in comparison with the conventional treatment.
- 1 October 2008
- Vol. 30 (5)
Cellular uptake and ex vivo urothelial penetration by oligodeoxynucleotides for optimizing treatment of transitional cell carcinoma.
To evaluate cellular uptake and urothelial penetration of oligodeoxynucleotides (ODNs) in transitional cell carcinoma (TCC) cell lines and in a porcine ex vivo model, respectively.
- 1 October 2008
- Vol. 30 (5)
Cellular uptake and ex vivo urothelial penetration by oligodeoxynucleotides for optimizing treatment of transitional cell carcinoma.
To evaluate cellular uptake and urothelial penetration of oligodeoxynucleotides (ODNs) in transitional cell carcinoma (TCC) cell lines and in a porcine ex vivo model, respectively.
- 1 August 2008
- Vol. 30 (4)
Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
To compare serum vascular endothelial growth factor C (VEGF-C) levels in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze VEGF-C levels in relation to clinicopathologic parameters.
- 1 August 2008
- Vol. 30 (4)
Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
To compare serum vascular endothelial growth factor C (VEGF-C) levels in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze VEGF-C levels in relation to clinicopathologic parameters.
- 31 March 2008
- Published by Elsevier in European Urology
- Vol. 53 (3) , 571-580
Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder
- 31 March 2008
- Published by Elsevier in European Urology
- Vol. 53 (3) , 571-580
Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder
- Open Access
- 1 February 2006
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 59 (1) , 25-30
La influencia de la "resección transuretral diferenciada" en la recurrencia y progresión en cáncer vesical superficial
Objetivo: Los datos experimentales muestran correlación entre el área de urotelio dañado y la tasa de recurrencia en cáncer superficial de la vejiga. La adherencia de las células tumorales aumenta frente a la exposición da la matriz extracelular (ECM). La resección transuretral de los tumores vesicales (TURB) descubre el ECM y puede favorecer la recurrencia. La pregunta si la recurrencia aumenta en los casos de grandes áreas de resección es difícil de contestar, porque nunca habrá estudios prospectivos al respecto. En este estudio investigamos si lesiones del urotelio más profundas y más grandes, como las que son causadas por resecciones diferenciadas se relacionan con mayores tasas de recurrencia y progresión que resecciones regulares de los tumores vesicales. Métodos: 163 pacientes con cáncer vesical superficial fueron evaluados retrospectivamente. 66 fueron tratados con una TURB diferenciada y 97 con una TURB regular. Analizamos las tasas de recurrencia y progresión en un seguimiento mínimo de 48 meses, así como la persistencia de tumor en la re-resección. Resultados: Los pacientes sometidos a TURB diferenciada mostraron no tener ninguna incidencia más alta de recurrencia y/o de progresión del tumor, pero mostraron un porcentaje significativamente más alto de resecciones libres de tumor en la re-resección. Conclusiones: Como modelo de lesión urotelial mayor, la técnica de TURB diferenciada para cáncer superficial de vejiga no muestra ninguna influencia negativa en las tasas de recurrencia y progresión. Parece improbable que la matriz extracelular descubierta por la resección transuretral sea la razón principal de las altas tasas de recurrencia. Por otro lado, la significativa menor incidencia de persistencia tumoral en la segunda resección favorece a la técnica diferenciada de resección en el tratamiento transurethral de los tumores vesicales superficiales.
- 1 February 2006
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 59 (1) , 25-30
Open AccessLa influencia de la "resección transuretral diferenciada" en la recurrencia y progresión en cáncer vesical superficial
Objetivo: Los datos experimentales muestran correlación entre el área de urotelio dañado y la tasa de recurrencia en cáncer superficial de la vejiga. La adherencia de las células tumorales aumenta frente a la exposición da la matriz extracelular (ECM). La resección transuretral de los tumores vesicales (TURB) descubre el ECM y puede favorecer la recurrencia. La pregunta si la recurrencia aumenta en los casos de grandes áreas de resección es difícil de contestar, porque nunca habrá estudios prospectivos al respecto. En este estudio investigamos si lesiones del urotelio más profundas y más grandes, como las que son causadas por resecciones diferenciadas se relacionan con mayores tasas de recurrencia y progresión que resecciones regulares de los tumores vesicales. Métodos: 163 pacientes con cáncer vesical superficial fueron evaluados retrospectivamente. 66 fueron tratados con una TURB diferenciada y 97 con una TURB regular. Analizamos las tasas de recurrencia y progresión en un seguimiento mínimo de 48 meses, así como la persistencia de tumor en la re-resección. Resultados: Los pacientes sometidos a TURB diferenciada mostraron no tener ninguna incidencia más alta de recurrencia y/o de progresión del tumor, pero mostraron un porcentaje significativamente más alto de resecciones libres de tumor en la re-resección. Conclusiones: Como modelo de lesión urotelial mayor, la técnica de TURB diferenciada para cáncer superficial de vejiga no muestra ninguna influencia negativa en las tasas de recurrencia y progresión. Parece improbable que la matriz extracelular descubierta por la resección transuretral sea la razón principal de las altas tasas de recurrencia. Por otro lado, la significativa menor incidencia de persistencia tumoral en la segunda resección favorece a la técnica diferenciada de resección en el tratamiento transurethral de los tumores vesicales superficiales.
- 28 July 2004
- Vol. 24, 1651-6
Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation.
The microvessel density (MVD) is often used as a quantitative parameter for angiogenesis. The aim of this study was to evaluate the three most commonly used endothelial markers of microvessels, CD31, CD34 and vWF, in benign and malignant prostatic tissue. Fifteen benign hyperplastic prostate and 54 prostate cancer specimens were immunohistochemically stained for CD31/CD34/vWF. The MVD obtained by each marker was quantified by a vessel count in standardized grids within the area of maximum angiogenesis. The data on MVD was interrelated and compared to tumor staging, grading and clinical follow-up. A significant correlation of the CD31/CD34/vWF-MVD data was observed in BPH tissue, but not in PCa. In PCa, the most sensitive marker for newly derived blood vessels was CD34. While CD34-MVD demonstrated a significant association with tumorgrading and PSA follow-up, CD31- or vWF-MVD did not. CD34 is a suitable marker for the immunohistochemical visualization of microvessels in benign and malignant prostate tissue.
- 28 July 2004
- Vol. 24, 1651-6
Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation.
The microvessel density (MVD) is often used as a quantitative parameter for angiogenesis. The aim of this study was to evaluate the three most commonly used endothelial markers of microvessels, CD31, CD34 and vWF, in benign and malignant prostatic tissue. Fifteen benign hyperplastic prostate and 54 prostate cancer specimens were immunohistochemically stained for CD31/CD34/vWF. The MVD obtained by each marker was quantified by a vessel count in standardized grids within the area of maximum angiogenesis. The data on MVD was interrelated and compared to tumor staging, grading and clinical follow-up. A significant correlation of the CD31/CD34/vWF-MVD data was observed in BPH tissue, but not in PCa. In PCa, the most sensitive marker for newly derived blood vessels was CD34. While CD34-MVD demonstrated a significant association with tumorgrading and PSA follow-up, CD31- or vWF-MVD did not. CD34 is a suitable marker for the immunohistochemical visualization of microvessels in benign and malignant prostate tissue.
- 25 June 2003
- Vol. 23, 1473-8
Intrinsic presence of poly (ADP-ribose) is significantly increased in malignant prostate compared to benign prostate cell lines.
Poly(ADP-ribosyl)ation plays important roles in cellular DNA repair mechanisms as well as in cellular proliferation and genomic stability. Four carcinoma cell lines, LNCaP, PC-3, C4-2 and MatLu, and one prostate epithelial cell line, PNT1A, were tested using the H10 antibody to poly(ADP-ribose) by Western blotting and FACS analysis for basal and activated (10 mM H2O2) PARP activity. In both analyses, higher levels of basal polymer were present in the LNCaP cell line than in the prostate epithelial cell line or the MatLu cell an line. LNCaP cells demonstrated greater than 90% positive analyzed cells in FACS analysis both before and after treatment with H2O2. PNT1A epithelial cells demonstrated evidence of polymer presence only after treatment with H2O2. Microsatellite instability due to increased oxidative damage in tumor cells has been proposed as a means for accumulation of genetic changes. As oxidative stress can stimulate poly(ADP-ribose) reactions, an increased presence of the polymer may indicate a high level of oxidative damage occurring in the tumor cells, contributing to higher levels of genetic instability towards progression.
- 25 June 2003
- Vol. 23, 1473-8
Intrinsic presence of poly (ADP-ribose) is significantly increased in malignant prostate compared to benign prostate cell lines.
Poly(ADP-ribosyl)ation plays important roles in cellular DNA repair mechanisms as well as in cellular proliferation and genomic stability. Four carcinoma cell lines, LNCaP, PC-3, C4-2 and MatLu, and one prostate epithelial cell line, PNT1A, were tested using the H10 antibody to poly(ADP-ribose) by Western blotting and FACS analysis for basal and activated (10 mM H2O2) PARP activity. In both analyses, higher levels of basal polymer were present in the LNCaP cell line than in the prostate epithelial cell line or the MatLu cell an line. LNCaP cells demonstrated greater than 90% positive analyzed cells in FACS analysis both before and after treatment with H2O2. PNT1A epithelial cells demonstrated evidence of polymer presence only after treatment with H2O2. Microsatellite instability due to increased oxidative damage in tumor cells has been proposed as a means for accumulation of genetic changes. As oxidative stress can stimulate poly(ADP-ribose) reactions, an increased presence of the polymer may indicate a high level of oxidative damage occurring in the tumor cells, contributing to higher levels of genetic instability towards progression.